AU2023357899A1 - Design method and production method for nucleic acid construct and protein complex - Google Patents

Design method and production method for nucleic acid construct and protein complex Download PDF

Info

Publication number
AU2023357899A1
AU2023357899A1 AU2023357899A AU2023357899A AU2023357899A1 AU 2023357899 A1 AU2023357899 A1 AU 2023357899A1 AU 2023357899 A AU2023357899 A AU 2023357899A AU 2023357899 A AU2023357899 A AU 2023357899A AU 2023357899 A1 AU2023357899 A1 AU 2023357899A1
Authority
AU
Australia
Prior art keywords
seq
protein
seqididno
drb1
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023357899A
Other languages
English (en)
Inventor
Tadao Okamoto
Hidetoshi Takada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tsukuba NUC
Original Assignee
University of Tsukuba NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Tsukuba NUC filed Critical University of Tsukuba NUC
Publication of AU2023357899A1 publication Critical patent/AU2023357899A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001114—CD74, Ii, MHC class II invariant chain or MHC class II gamma chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/00114—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2023357899A 2022-10-07 2023-10-06 Design method and production method for nucleic acid construct and protein complex Pending AU2023357899A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022162824 2022-10-07
JP2022-162824 2022-10-07
PCT/JP2023/036654 WO2024075851A1 (ja) 2022-10-07 2023-10-06 核酸構築物およびタンパク複合体の設計方法および製造方法

Publications (1)

Publication Number Publication Date
AU2023357899A1 true AU2023357899A1 (en) 2025-05-01

Family

ID=90608080

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023357899A Pending AU2023357899A1 (en) 2022-10-07 2023-10-06 Design method and production method for nucleic acid construct and protein complex

Country Status (5)

Country Link
EP (1) EP4600361A1 (https=)
JP (1) JPWO2024075851A1 (https=)
CN (1) CN120019151A (https=)
AU (1) AU2023357899A1 (https=)
WO (1) WO2024075851A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190351040A1 (en) * 2017-02-01 2019-11-21 Modernatx, Inc. Rna cancer vaccines
JP7623879B2 (ja) 2021-04-13 2025-01-29 株式会社日立製作所 行動制御計画装置、行動制御計画方法及び行動制御計画システム

Also Published As

Publication number Publication date
WO2024075851A1 (ja) 2024-04-11
JPWO2024075851A1 (https=) 2024-04-11
CN120019151A (zh) 2025-05-16
EP4600361A1 (en) 2025-08-13

Similar Documents

Publication Publication Date Title
Yang et al. The update immune-regulatory role of pro-and anti-inflammatory cytokines in recurrent pregnancy losses
Koch et al. Th9 and other IL-9-producing cells in allergic asthma
US20240392002A1 (en) Anti-ror antibody constructs
Seo et al. Crucial roles of interleukin-7 in the development of T follicular helper cells and in the induction of humoral immunity
Takatsu Interleukin-5 and IL-5 receptor in health and diseases
Wang et al. The potential role of interleukin-17 in severe asthma
Gaffen Biology of recently discovered cytokines: interleukin-17–a unique inflammatory cytokine with roles in bone biology and arthritis
Gibbs Human basophils as effectors and immunomodulators of allergic inflammation and innate immunity
Paganelli et al. Humoral immunity in aging
CN114072164A (zh) Il-10变体分子和治疗炎性疾病和肿瘤的方法
Chaplin et al. Anti-CD180 (RP105) activates B cells to rapidly produce polyclonal Ig via a T cell and MyD88-independent pathway
TW200539890A (en) Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function
JP2009543579A (ja) 抗炎症反応のための標的としてのＷＳＸ−１／ｐ２８
JP2012184259A (ja) 哺乳動物のサイトカイン；関連する試薬の使用
Worm et al. Molecular regulation of human IgE synthesis
Akdis et al. Cytokine network and dysregulated apoptosis in atopic dermatitis
AU2009203080A1 (en) Methods for Modulating an Inflammatory Response
KR20220109435A (ko) B형 간염 감염 치료에서의 사용을 위한 인터페론-결합된 항원 결합 단백질
JP3657271B2 (ja) 病原性または日和見感染性生物に感染した哺乳動物の治療のための組成物
WO2021190431A1 (zh) 一种免疫细胞激活剂的开发及应用
Teng et al. Characterization of chicken interleukin 2 receptor α chain, a homolog to mammalian CD25
US12595300B2 (en) Anti-human P40 protein domain antibody and use thereof
WO2015190555A1 (ja) 多重同種抗原ペプチド
Cao et al. The protozoan commensal Tritrichomonas musculis is a natural adjuvant for mucosal IgA
Jiang et al. MOG35–55 iv suppresses experimental autoimmune encephalomyelitis partially through modulation of Th17 and JAK/STAT pathways